Botulinum toxin A - Medytox

Drug Profile

Botulinum toxin A - Medytox

Alternative Names: KbtxA; Meditoxin injection - Medy-Tox; MT 10107; MT 10109; Neuronox

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Medy-Tox
  • Developer Medytox
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
  • Phase II Hypertrophy; Torticollis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Jul 2015 Botulinum toxin licensed to Medybloom in China
  • 01 Aug 2014 Phase-II clinical trials in Hypertrophy in South Korea (IM) (NCT02292472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top